What question did this study set out to answer?

To explore the anti-tumor effects of the PCNA inhibitor AOH-1996 in multiple myeloma and its impact on miRNA and cancer stem cell markers.

Targeting Proliferating Cell Nuclear Antigen for Treating Multiple Myeloma

View Full Paper

Ask AI

Bookmark

Authors

This research demonstrates the therapeutic potential of targeting PCNA in multiple myeloma, highlighting its significance in treatment strategies.

To explore the anti-tumor effects of the PCNA inhibitor AOH-1996 in multiple myeloma and its impact on miRNA and cancer stem cell markers.
Tested AOH-1996 alone and with bortezomib or venetoclax on multiple myeloma cell lines.
Assessed anti-MM effects using viability assays and 3D spheroid degradation.
Analyzed gene expression changes via RT-qPCR and Western blotting after AOH-1996 exposure.
Conducted xenograft studies to evaluate AOH-1996 efficacy in vivo.
AOH-1996 reduced cell growth and CSC-like sphere formation in a dose-dependent manner.
Treatment delayed mitosis in MM cells and down-regulated anti-apoptotic and cancer stem cell markers.
MiRNA analysis revealed down-regulation of oncogenic miRNAs and up-regulation of anti-oncogenic miR-145.
AOH-1996 combined with bortezomib or venetoclax showed a synergistic effect against MM cells.

Zonder et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

This research demonstrates the therapeutic potential of targeting PCNA in multiple myeloma, highlighting its significance in treatment strategies.